Monopar Therapeutics (NASDAQ:MNPR) Coverage Initiated by Analysts at Chardan Capital

Chardan Capital began coverage on shares of Monopar Therapeutics (NASDAQ:MNPR) in a research note released on Monday morning, Marketbeat Ratings reports. The brokerage issued a buy rating and a $60.00 price objective on the stock.

Several other equities analysts also recently issued reports on the stock. Jones Trading restated a “hold” rating on shares of Monopar Therapeutics in a report on Wednesday, April 2nd. Piper Sandler restated an “overweight” rating and set a $76.00 price target on shares of Monopar Therapeutics in a research note on Wednesday, March 19th. HC Wainwright reaffirmed a “buy” rating and issued a $40.00 price target on shares of Monopar Therapeutics in a report on Tuesday, April 1st. Finally, Wall Street Zen upgraded shares of Monopar Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, May 22nd. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $56.50.

Monopar Therapeutics Price Performance

Monopar Therapeutics stock opened at $31.83 on Monday. Monopar Therapeutics has a 1-year low of $1.72 and a 1-year high of $54.30. The business has a fifty day moving average price of $37.18 and a 200-day moving average price of $34.62. The stock has a market capitalization of $194.80 million, a price-to-earnings ratio of -9.15 and a beta of 1.00.

Monopar Therapeutics (NASDAQ:MNPR) last released its quarterly earnings results on Tuesday, May 13th. The company reported ($0.38) EPS for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.27. On average, equities research analysts anticipate that Monopar Therapeutics will post -1.65 earnings per share for the current fiscal year.

Insider Activity at Monopar Therapeutics

In other news, major shareholder Tactic Pharma Llc sold 33,334 shares of the stock in a transaction on Wednesday, April 2nd. The shares were sold at an average price of $35.00, for a total value of $1,166,690.00. Following the sale, the insider now owns 822,255 shares in the company, valued at $28,778,925. This represents a 3.90% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 20.50% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. AlphaQuest LLC purchased a new position in shares of Monopar Therapeutics during the 1st quarter valued at about $44,000. JPMorgan Chase & Co. purchased a new stake in shares of Monopar Therapeutics in the fourth quarter worth about $45,000. Gerber LLC acquired a new stake in Monopar Therapeutics during the first quarter worth about $204,000. OMERS ADMINISTRATION Corp purchased a new position in Monopar Therapeutics during the first quarter valued at approximately $328,000. Finally, Jane Street Group LLC purchased a new position in Monopar Therapeutics during the first quarter valued at approximately $377,000. 1.83% of the stock is currently owned by institutional investors and hedge funds.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.